Cencora's Specialty Strategy Expected to Drive Growth Through Fiscal 2027
Cencora (NYSE:COR) is confident its specialty-focused strategy will continue driving growth through fiscal 2027, supported by strong demand in oncology and retina segments. The company highlighted expanded physician-services capabilities, contributions from OneOncology, international momentum, and ongoing investments as key drivers of future performance. Cencora's CEO Bob Mauch emphasized the importance of its position in specialty pharmaceuticals across health systems and community practices. CFO Eva Boratto noted that prescription utilization trends have rebounded after a brief dip earlier this year and are expected to remain consistent through Q3, supporting positive fourth-quarter growth expectations despite some volume shifts with Walgreens. The company remains focused on capital allocation strategies including share repurchases, dividend increases, and maintaining financial strength. Cencora plans to provide more detailed fiscal 2027 guidance during its November earnings call.
Tickers: $COR
Topics: growth strategy international expansion oncology retina care specialty pharmaceuticals